Abstract
Objective To study the effects of symbicort turbuhaler combined with theophylline sustained-release tablets on lung function and serum T cell subsets in patients with bronchial asthma in remission stage. Methods A total of 114 patients with bronchial asthma in remission stage in our hospital from October 2016 to May 2018 were enrolled, and were divided into study group (n=57) and control group (n=57) with the randomized digital table. Both groups were given routine symptomatic treatment. On the basis, the control group was treated with symbicort turbuhaler, and the study group was added with theophylline sustained-release tablets on the basis of the control group. Treatment effects, lung function indexes [forced expiratory volume at 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEF)], serum inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin 4 (IL-4)], and serum T cell subsets (CD4+, CD4+/CD8+) levels before and after treatment were compared between the two groups. Results (1) The total effective rate of the study group [96.49% (55/57)] was higher than that of the control group [80.70% (46/57)] (P<0.05). (2) The values of FEV1, PEF, FVC after treatment in the two groups were higher than those before treatment, and those in the study group were higher than those in the control group (P<0.05). (3) The levels of TNF-α and IL-4 in the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P<0.05). (4) After treatment, CD4+, CD4+/CD8+ of the study group were higher than those of the control group (P<0.05). Conclusions Symbicort turbuhaler combined with theophylline sustained-release tablets can significantly improve the therapeutic effect in patients with bronchial asthma in remission stage, further reduce the serum inflammatory factors levels, improve the body's immune function, and thus improve the lung function of patients, with a certain degree of security. Key words: Bronchial asthma; Symbicort turbuhaler; Theophylline sustained release tablets; Lung function; T cell subsets; Inflammatory factors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.